The PARAGLIDE-HF trial by Mentz et al. concluded that, among patients with HFmrEF and HFpEF, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP levels and was associated with clinical benefits compared with valsartan alone [13]. Here, NPPB is linked to hydrops fetalis.